Condition: Large B-cell Lymphoma · DLBCL - Diffuse Large B Cell Lymphoma · Sponsor: Abramson Cancer Center at Penn Medicine
The research study is being conducted to test the safety and effectiveness of the experimental drug mosunetuzumab (Cohort 1) or obinutuzumab and glofitamab (Cohort 2) when given after CAR (genetically modified) T cells. The study is for patients who have already received a CAR T-cell infusion. Some patients who join the study will receive mosunetuzumab, other patients later in the study may receive a different experimental drug (glofitamab, in combination with obinutuzumab).
This description comes directly from the study's public registry record.
Rachel Lundberg, PA-C · 215-615-5858 · Rachel.Lundberg@pennmedicine.upenn.edu
Kaitlin Kennard, RN · 215-615-5858 · Kaitlin.Kennard@pennmedicine.upenn.edu
Always discuss trial participation with your own doctor first.
| University of Nebraska Medical Center | Omaha, Nebraska, United States | Recruiting |
| Abramson Cancer Center of the University of Pennsylvania | Philadelphia, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04889716